



FORM 7
MONTHLY PROGRESS REPORT FOR THE MONTH ENDED FEBRUARY 28, 2019

Name of Listed Issuer: MPX International Corporation (“MPXI” or the “Issuer”).

Trading Symbol: MPXI

Number of Outstanding Listed Securities: 46,383,542

Date: March 7, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.*
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.*
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.*

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On February 5, 2019, the Issuer, MPX Bioceutical Corporation ("**MPX Bioceutical**"), and iAnthus Capital Holdings, Inc. ("**iAnthus**") closed the plan of arrangement (the "**Arrangement**") under the *Business Corporations Act* (British Columbia) pursuant to which iAnthus acquired all of the issued and outstanding common shares of MPX Bioceutical (the "**MPX Bioceutical Shares**") pursuant to the terms of an arrangement agreement, as amended, among, inter alia, iAnthus and MPX dated October 18, 2018 (the "**Arrangement Agreement**").

Pursuant to the terms of the Arrangement Agreement, holders of MPX Bioceutical Shares received 0.1673 common shares of iAnthus for each MPX Bioceutical Share held. In addition, each MPX shareholder received 0.1 common shares of MPXI.

In connection with the Arrangement, the Corporation acquired the following:

- (i) MPX Bioceutical Australia Ltd., Salus BioPharma Corporation, Biocannabis Products Ltd., Canveda Inc. (formerly 8423695 Canada Inc.) ("**Canveda**"), The CinG-X Corporation and Spartan Wellness Corporation;
- (ii) all current assets related to the entities specified in (i) above, including but not limited to, cash,
- (iii) accounts receivable, inventory, biological assets, prepaid expenses, amounts due from related
- (iv) parties, amounts due in connection with any right(s) of first refusal, assets held for sale and
- (v) deferred financing costs and deposits;
- (vi) the office leases of MPX Bioceutical relating to MPX's existing offices located at 701-5255 Yonge Street, Toronto, Ontario, M2N 6P4, 702-5255 Yonge Street, Toronto, Ontario, M2N 6P4, 760 Technology Drive, Peterborough, Ontario, K9J 6X7 and 1799 20th Street East, Owen Sound, Ontario, N4K 1Z4;
- (vii) office furniture, office equipment or office supplies located at the locations referred to in clause above;
- (viii) all fixed assets located at the locations referred to in clause (iii) above or located within the boundaries of the locations referred to in clause (iii) above;
- (ix) the industry partner participation and sponsorship agreement dated September 24, 2018 between Volteface and MPX Bioceutical;
- (x) any tax-loss carry forwards belonging to MPX Bioceutical and all entities referred to in (i) above;
- (xi) a royalty free, exclusive and perpetual license to MPX Bioceutical's brand, intellectual property, extraction and formulation, standard operating procedures and production technologies worldwide, other than in the United States, pursuant to an agreement between MPXI and MPX Bioceutical (the "**MPX IP Agreement**"), which for greater certainty shall not restrict MPXI from any further investment in the U.S. cannabis industry and will be subject to mutual obligations and performance obligations as approved by iAnthus, acting reasonably;
- (xii) all agreements entered into with Panaxia Pharmaceutical Industries Ltd.;
- (xiii) a subcontractor agreement between MPXI and ABACA, LLC; and
- (xiv) the right to use the name "MPX International Corporation" pursuant to the MPX IP Agreement.

The Issuer commenced trading on February 6, 2019.

Canveda, a wholly-owned subsidiary of the Issuer, received its sale for medical purposes and standard processing licences effective as of February 22, 2019 for its facility in Peterborough, Ontario. The licence will allow Canveda, conditional upon Health Canada's final pre-sales inspection, to develop its medical patient and product strategy and to commence selling their own products directly to registered patients for medical purposes. In the meantime, Canveda will continue selling dried flower products to other Licenced Producers with medical sales licences. The processing licence will allow Canveda to commence processing of dried cannabis into other formats including capsules and pre-rolls.

Following approval from Health Canada, Canveda imported 28 new strains of cannabis from a supplier in the Netherlands and proceeded with the cultivation of several of these new strains with a first harvest scheduled for April 2019. Cultivation of these new high-quality strains will provide Canveda with a multitude of different varieties of cannabis over the next few production cycles. The Canveda facility is now in full production and is expected to produce 1.2 million grams of high-quality cannabis flower over the next 12 months.

Additionally, Canveda is licenced to produce cannabis oils and capsules and has commenced the build-out of a small production laboratory expected to be operational by late Q2 2019. Once the initial two batches of oil have passed successful qualitative analysis, Canveda will request oils to be included in its medical sales licence. Once licenced, the production facility will operate temporarily pending completion of the much larger project in Owen Sound, Ontario.

While MPX International is continuing to develop opportunities in the emerging global cannabis marketplace, the expectation is that the Issuer's Canveda facility in Peterborough, amongst others, will be one of the first to generate significant revenues.

On February 26, 2019, the Issuer granted 3,175,000 stock options to purchase common shares of MPXI to officers, directors, employees and consultants of the Issuer and its subsidiaries at an exercise price of \$0.59 per share and expiring on February 26, 2024.

2. Provide a general overview and discussion of the activities of management.

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

8. **Describe the acquisition of new customers or loss of customers.**

None.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at www.sedar.com.

10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

None.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None.

14. Provide details of any securities issued and options or warrants granted.

During February 2019, the Issuer issued the following securities:

Date	Type of Security	Price per Security (CAD)	Number of Securities Issued or Issuable
February 5, 2019	Common Shares		45,304,966 ⁽¹⁾
February 26, 2019	Common Shares		1,078,576 ⁽²⁾
February 26, 2019	Stock Options	\$0.59	1,609,737 ⁽³⁾

Notes:

- (1) On February 5, 2019, 45,304,966 common shares were issued pursuant to the Arrangement.
- (2) On February 26, 2019, 1,078,576 stock options were exercised into common shares of the Issuer.
- (3) On December 13, 2018, 3,175,000 stock options were granted to officers, directors, employees and consultants of the Issuer and its subsidiaries at an exercise price of \$0.59 per share and expiring on February 26, 2024.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

After completion of the Arrangement, MPXI's board of directors is comprised of W. Scott Boyes, Jeremy S. Budd, Alastair Crawford, Robert Petch and Randall G. Stafford. Messrs Crawford, Petch and Stafford sit on all three (3) committees: (a) audit committee; (b) compensation committee; and (c) corporate governance and nominating committee.

MPXI's officers are W. Scott Boyes (Chairman, President & Chief Executive Officer), David McLaren (Chief Financial Officer) and Jeremy S. Budd (Executive Vice President, General Counsel and Corporate Secretary).

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer will be focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

Initially, the Issuer will concentrate on developing its assets in Canada, while continuing to evaluate and develop opportunities in the European Union, United Kingdom and Australia.

In its Summer 2018 edition of the European Cannabis Report, the leading industry advisory firm, Prohibition Partners estimated that the European cannabis market would grow to €115 billion (US\$177 billion) by 2028, virtually double the size of the forecast U.S. market. The same firm's estimate in its November issue of the Oceania Cannabis Report projected that total market size in Australia and Oceania to be approximately US\$23 billion (including CBD products). These markets are in the early stages of development compared to the industry in North America and the Issuer will focus on establishing early-mover advantage as the regulations in the respective countries continue to evolve. On the Effective Date, the Issuer anticipates that it will continue to have the

support of a large contingent of international shareholders, which it believes will strengthen its international expansion efforts. The Issuer will spend time partnering with advisory and industry support groups across several countries and expects to be in a position to leverage managements relationship with key industry suppliers, leaving it well-positioned to take a quick foothold in these emerging cannabis markets.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 7, 2019.

Jeremy S. Budd

Name of Director or Senior Officer

signed "Jeremy S. Budd"

Signature

Executive VP, General Counsel,
Corporate Secretary and a director

Official Capacity

Issuer Details	For Month End	Date of Report
<i>Name of Issuer</i> MPX International Corporation	February 2019	YY/MM/DD 19/03/07
<i>Issuer Address</i> Yonge Norton Centre, 5255 Yonge Street, Suite 701		
<i>City/Province/Postal Code</i> Toronto, Ontario, M2N 6P4	<i>Issuer Fax No.</i> 1-877-595-1828	<i>Issuer Telephone No.</i> (416) 840-3725
<i>Contact Name</i> W. Scott Boyes	<i>Contact Position</i> Chairman, President and CEO	<i>Contact Telephone No.</i> (416) 840-3725
<i>Contact Email Address</i> info@mpxinternationalcorp.com	<i>Web Site Address</i> www.mpxinternationalcorp.com	